Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BSenhwa Biosciences 〉CX-5461-G-quadruplex stabilizer

CX-5461-G-quadruplex stabilizer

CX-5461-G-quadruplex stabilizer

CX-5461, a synthetically derived small molecule, is supplied as a lyophilized drug with intravenous (IV) administration.

Request for Collaboration
Synthetic lethality (SL) is a concept in which cell death is induced by the combination of two non-lethal mutations, while mutation alone is not sufficient to affect cell survival.  Recently, SL has been proposed as a novel anticancer strategy that is promising to be highly selective.  If a cancer-specific mutation combined with a drug-induced mutation have SL interactions, it will selectively kill cancer cells but not normal cells.  For example, tumors with DNA repair defects, such as those arising from patients with BRCA mutations, were found to be more sensitive to PARP inhibition due to synthetic lethality.  The BRCA genes encode large proteins with complex functions in DNA repair and cell cycle checkpoint control.  Since BRCA mutated tumors cannot utilize homologous recombination (HR) to repair double-strand breaks, exposing these cells to a PARP inhibitor, which shuts down the base excision repair (BER) rescue pathway, will lead to the accumulation of DNA damage, genomic instability and cell death.
Nucleic acids, which include DNA and RNA, are among the most important biological macromolecules and carry the genetic information within cells.  G-quadruplexes (G4) are four-stranded nucleic acid secondary structures that are over-represented in gene promoter regions and are viewed as emerging therapeutic targets in oncology.  G4 sequences are highly prevalent in the human genome and are involved in DNA replication, gene expression and regulation, telomere/chromosome maintenance and genomic instability.  When the G4 structure is stabilized by drug-like molecules, it may cause replication fork stalling, DNA breaks, and transcription–replication collisions, resulting in tumor cell death.  Therefore, the development of novel stabilizers of G4 is an exciting anticancer approach in the potentially broad clinical applicability.
CX-5461 is a G4-stabilizing compound and able to stabilize the folded conformation and lead to replication fork stalling and unreplicated chromosomal areas, while acting in concert with HR pathway deficiency, such as BRCA1/2 mutations, which stalls replication forks undergo DNA breaks and thus causes cancer cell death.  Accordingly, stabilization of G4 at the replication fork, it can result in substantial genomic instability and DNA breaks.  In homologous recombination deficiency (HRD) tumors, the cells' deficiency in self-repairing means these cancers carry a high load of DNA mutations and are genomically unstable.  CX-5461 in combination with HRD tumors may be exploited through a synthetic lethality approach for the application of anticancer therapy targeting DNA repair defects in HRD tumors.
CX-5461 has demonstrated a favorable preclinical profile.  Several in vivo models have shown a superior activity spectrum of CX-5461 in comparison to PARP inhibitor and platinum salts in BRCA or HR deficient tumors.  Based on the preclinical data, a Phase I/II clinical trial of CX-5461 to evaluate the concept of G4 targeting in BRCA- or HR-deficient breast cancer has started in Canada in Q2 2016.  This study is conducted by the Canadian Cancer Trials Group (CCTG) and is supported by Senhwa and the Stand Up To Cancer Canada (SU2C Canada).

CX-5461 Mechanism

Breast Cancer (Triple Negative Breast Cancer)
Ovarian Cancer
Prostate Cancer
Pancreatic Cancer
Patent Portfolio
Senhwa's patent portfolio is comprised of 105 issued patents and 14 pending patent applications (by 19 May, 2017).  Intellectual property rights include patents covering product derivatives, pharmaceutical formulations, method of use, manufacturing process, crystalline forms and combination therapies.  Patents have been granted in the US, Europe, Canada, Japan, South Korea, China, Hong Kong, Russia, Australia, New Zealand and Taiwan.  Especially in the Europe, there are 19 countries have been registered to extent the market size for cancer therapy, including Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, United Kingdom.
Collaboration Options
More Information
People who like this also like
  • TAH4411 Antiemetic Oral Thin FilmTAH4411 Antiemetic Oral Thin Film
  • Burixafor (TG-3000)Burixafor (TG-3000)
  • R&D ManagementR&D Management
  • Homogeneous antibody drugs (CHO-H01, H02, H03)Homogeneous antibody drugs (CHO-H01, H02, H03)
  • PHN031 (Osteoporosis prevention)PHN031 (Osteoporosis prevention)
  • Non-invasive Fiber Optic Physiological Monitoring TechnologyNon-invasive Fiber Optic Physiological Monitoring Technology
  • Platform_NanoX™Platform_NanoX™
  • TLC388TLC388
  • RNTA06RNTA06